Canntab Therapeutics Past Earnings Performance
Past criteria checks 0/6
Canntab Therapeutics's earnings have been declining at an average annual rate of -12.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 4% per year.
Key information
-12.4%
Earnings growth rate
-0.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -4.0% |
| Return on equity | n/a |
| Net Margin | -4,566.8% |
| Last Earnings Update | 28 Feb 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Canntab Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 28 Feb 23 | 0 | -3 | 1 | 0 |
| 30 Nov 22 | 0 | -3 | 2 | 0 |
| 31 Aug 22 | 0 | -4 | 2 | 0 |
| 31 May 22 | 0 | -4 | 3 | 0 |
| 28 Feb 22 | -1 | -5 | 3 | 0 |
| 30 Nov 21 | 0 | -5 | 3 | 0 |
| 31 Aug 21 | 0 | -4 | 3 | 0 |
| 31 May 21 | 0 | -4 | 3 | 0 |
| 28 Feb 21 | 1 | -3 | 3 | 0 |
| 30 Nov 20 | 0 | -3 | 3 | 0 |
| 31 Aug 20 | 0 | -3 | 3 | 0 |
| 31 May 20 | 0 | -3 | 2 | 0 |
| 29 Feb 20 | 0 | -2 | 2 | 0 |
| 30 Nov 19 | 0 | -2 | 2 | 0 |
| 31 Aug 19 | 0 | -2 | 2 | 0 |
| 31 May 19 | 0 | -2 | 2 | 0 |
| 28 Feb 19 | 0 | -4 | 2 | 0 |
| 30 Nov 18 | 0 | -3 | 2 | 0 |
| 31 Aug 18 | 0 | -3 | 2 | 0 |
| 31 May 18 | 0 | -2 | 1 | 0 |
| 28 Feb 18 | 0 | -1 | 1 | 0 |
| 30 Nov 17 | 0 | -2 | 1 | 0 |
| 31 Aug 17 | 0 | -1 | 1 | 0 |
Quality Earnings: TBF1 is currently unprofitable.
Growing Profit Margin: TBF1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TBF1 is unprofitable, and losses have increased over the past 5 years at a rate of 12.4% per year.
Accelerating Growth: Unable to compare TBF1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TBF1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: TBF1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.